PSTI - プルリステム・セラピュ―ティクス （Pluristem Therapeutics Inc.）

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pluristem Therapeutics Changes its Name To Pluri Pluristem Therapeutics Inc (NASDAQ: PSTI ) will be renamed Pluri Inc and start trading on NASDAQ under the ticker PLUR from July 26. The change reflects a broader strategy of leveraging its 3D cell expansion technology to develop cell-based products that can be harnessed for various fields beyond medicine. AstraZeneca''s Enhertu Under FDA Priority Review For HER2-Low Metastatic Breast Cancer The FDA has accepted AstraZeneca Plc (NASDAQ: AZN ) and Daiichi Sankyo''s (OTC: DSNKY ) supplemental application seeking approval for Enhertu (trastuzumab deruxtecan) for unresectable or metastatic HER2-low breast cancer who have received a prior therapy in the metastatic setting. The application has been granted Priority Review. The Prescription Drug User Fee Act date is during Q4 of 2022. Shares are up 1.66% at $66.33 during the premarket session. CHMP Recommends Approving AstraZeneca''s Asthma, Neuromuscular Disorder Treatments The European Medicines Agency''s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc''s (NASDAQ: AZN ) Ultomiris (ravulizumab) for generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Pluristem Therapeutics (PSTI) said it changed its name to Pluri Inc

Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short Physical Performance Battery (SPPB) test at week 26. The SPPB is a series of physical performance tests used in … Full story available on Benzinga.com

The clinical-stage biotech Pluristem Therapeutics (PSTI) said on Wednesday that its Phase 3 study for PLX-PAD cells as a treatment for muscle injury following hip fracture surgery, did…

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pluristem Therapeutics Changes its Name To Pluri Pluristem Therapeutics Inc (NASDAQ: PSTI ) will be renamed Pluri Inc and start trading on NASDAQ under the ticker PLUR from July 26. The change reflects a broader strategy of leveraging its 3D cell expansion technology to develop cell-based products that can be harnessed for various fields beyond medicine. AstraZeneca''s Enhertu Under FDA Priority Review For HER2-Low Metastatic Breast Cancer The FDA has accepted AstraZeneca Plc (NASDAQ: AZN ) and Daiichi Sankyo''s (OTC: DSNKY ) supplemental application seeking approval for Enhertu (trastuzumab deruxtecan) for unresectable or metastatic HER2-low breast cancer who have received a prior therapy in the metastatic setting. The application has been granted Priority Review. The Prescription Drug User Fee Act date is during Q4 of 2022. Shares are up 1.66% at $66.33 during the premarket session. CHMP Recommends Approving AstraZeneca''s Asthma, Neuromuscular Disorder Treatments The European Medicines Agency''s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc''s (NASDAQ: AZN ) Ultomiris (ravulizumab) for generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Pluristem Therapeutics (PSTI) said it changed its name to Pluri Inc

Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short Physical Performance Battery (SPPB) test at week 26. The SPPB is a series of physical performance tests used in … Full story available on Benzinga.com

The clinical-stage biotech Pluristem Therapeutics (PSTI) said on Wednesday that its Phase 3 study for PLX-PAD cells as a treatment for muscle injury following hip fracture surgery, did…

The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA

Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com

Pluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following…

Mainz Biomed (MYNZ) +14%. Vinco Ventures (BBIG) +13%. Digital World Acquisition (DWACW) +11%. Pluristem Therapeutics (PSTI) +10%

Pluristem Therapeutics Inc (PSTI) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 32.2% year-to-date, down 76.0% over the past 12 months, and down 87.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $2.04 and as low as $1.65 this week.Shares closed 77.6% below its 52-week high and 41.9% above its 52-week low.Trading volume this week was 96.1% lower than the 10-day average and 88.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -525.5% The company's stock price performance over the past 12 months lags the peer average by 130.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com